Reported resultsCompany-reported
What was reported
SOUTH SAN FRANCISCO, Calif. -- (May 4, 2026) — Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today reported financial results and business highlights for the second quarter ended March 31, 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 4, 2026 · Open the source ↗
What the evidence supports
Twist Bioscience published its results for the period in a press release furnished to the SEC (Form 8-K, Item 2.02).
What remains unknown
Audit status of the figures (results furnished on Form 8-K or 6-K are typically unaudited), and anything about future periods. Any outlook is the company's own projection. Figures and claims are the company's own description and have not been independently verified.
Figures as stated
Numbers exactly as written in the source. We don’t annualise, convert or add them up.
| Figure | In context |
|---|---|
| $110.7 million | “Revenue exceeded guidance, coming in at $110.7 million, growth of over 19% compared to the second quarter of 2025," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.” Mentions: revenue, guidance |
| $92.8 million | “•Revenue: Total revenues for the second quarter of fiscal 2026 grew 19% to $110.7 million compared to $92.8 million for the same period of fiscal 2025.” Mentions: revenue |
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineTwist Bioscience Reports Fiscal Second Quarter 2026 Financial ResultsU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 4, 2026 · Open the source ↗
Press release lead paragraphSOUTH SAN FRANCISCO, Calif. -- (May 4, 2026) — Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today reported financial results and business highlights for the second quarter ended March 31, 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 4, 2026 · Open the source ↗
Amount stated in press releaseRevenue exceeded guidance, coming in at $110.7 million, growth of over 19% compared to the second quarter of 2025," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 4, 2026 · Open the source ↗
Amount stated in press release•Revenue: Total revenues for the second quarter of fiscal 2026 grew 19% to $110.7 million compared to $92.8 million for the same period of fiscal 2025.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 4, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:51 UTC
Twist Bioscience Reports Fiscal Second Quarter 2026 Financial Results
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.